Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

Pituitary

Volumn 12, Issue 3, 2009, Pages 196-199

  Bianchi, Antonio ^a   Mazziotti, Gherardo ^b   Tilaro, Laura ^a   Cimino, Vincenzo ^a   Veltri, Flora ^a   Gaetani, Eleonora ^a   Pecorini, Giovanni ^a   Pontecorvi, Alfredo ^a   Giustina, Andrea ^b   De Marinis, Laura ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acromegaly; Exon 3; Growth hormone; Growth hormone receptor (GHR); Pegvisomant

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN;

ACROMEGALY; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; NEUROSURGERY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT FAILURE;

ACROMEGALY; ADULT; AGED; EXONS; FEMALE; HAPLOTYPES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, SOMATOTROPIN; YOUNG ADULT;

EID: 67849090089     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0157-8     Document Type: Article

References (20)

1. Kopchick JJ, Parkinson C, Stevens EC et al (2002) Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646. doi: 10.1210/er.2001-0022
2. Melmed S, Casanueva F, Cavagnini F et al (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740. doi: 10.1530/eje.1.02036
3. Muller AF, Kopchick JJ, Flyvbjerg A et al (2004) Clinical review 166: growth hormone receptor antagonists. J Clin Endocrinol Metab 89:1503-1511. doi: 10.1210/jc.2002-022049
4. Trainer PJ, Drake WM, Katznelson L et al (2000) Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. N Engl J Med 342:1171-1177. doi: 10.1056/NEJM200004203421604
5. van der Lely AJ, Hutson RK, Trainer PJ et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759. doi: 10.1016/S0140-6736(01)06844-1
6. Parkinson C, Burman P, Messig M et al (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92:190-195
7. Leung DW, Spencer SA, Cachianes G et al (1987) Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 330:537-543. doi: 10.1038/330537a0
8. Godowski PJ, Leung DW, Meacham LR et al (1989) Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A 86:8083-8087. doi: 10.1073/pnas.86.20.8083
9. Pekhletskv RI, Chernov BK, Rubtsov PM (1992) Variants of the 5'-untranslated sequence of human growth hormone receptor mRNA. Mol Cell Endocrinol 90:103-109. doi: 10.1016/0303-7207(92)90107-H
10. Urbanek M, Macleod JN, Cooke NE et al (1992) Expression of a human growth hormone (hGH) receptor isoform is predicted by tissue-specific alternative splicing of exon 3 of the hGH receptor - gene transcript. Mol Cell Endocrinol 6:279-287. doi: 10.1210/me.6.2.279
11. Wickelgren RB, Landin KL, Ohlsson C et al (1995) Expression of exon 3-retaining and exon 3-excluding isoforms of the human growth hormone-receptor is regulated in an interindividual, rather than a tissue-specific, manner. J Clin Endocrinol Metab 80:2154-2157. doi: 10.1210/jc.80.7.2154
12. Dos Santos C, Essioux L, Teinturier C et al (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724. doi: 10.1038/ ng1379
13. Binder G, Baur F, Schweizer R et al (2006) The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91:659-664. doi: 10.1210/jc.2005-1581
14. Jorge AA, Marchisotti FG, Montenegro LR et al (2006) Growth hormone (GH) pharmacokinetics: Influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 91:1076-1080. doi: 10.1210/ jc.2005-2005
15. Mercado M, González B, Sandoval C et al (2008) Clinical and biochemical impact of the d3 (fl) growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93(9):3411-3415. doi: 10.1210/ jc.2008-0391
16. Bianchi A, Giustina A, Cimino V et al. Influence of growth hormone receptor d3 and full-lenght isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab. (accepted)
17. Giustina A, Barkan A, Casanueva FF et al (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529. doi: 10.1210/jc.85.2.526
18. Pantel J, Machinis K, Sobrier ML et al (2000) Species-specificalternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664-18669. doi: 10.1074/jbc.M001615200
19. Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82. doi: 10.1530/eje.1.02312
20. Maffei P, Martini C, Pagano C et al (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 145:310-312